Literature DB >> 2539388

Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant.

S C Rall1, Y M Newhouse, H R Clarke, K H Weisgraber, B J McCarthy, R W Mahley, T P Bersot.   

Abstract

A family has been described in which type III hyperlipoproteinemia is associated with apo E phenotype E3/3 (Havel, R. J., L. Kotite, J. P. Kane, P. Tun, and T. Bersot. 1983. J. Clin. Invest. 72:379-387). In the current study, the structure of apo E from the propositus of this family was determined using both protein and DNA analyses. The propositus is heterozygous for two different apo E alleles, one coding for normal apo E3 and one for a previously undescribed variant apo E3 in which arginine replaces cysteine at residue 112 and cysteine replaces arginine at residue 142. Apo E gene analysis of nine other family members spanning four generations indicated that only those five members having type III hyperlipoproteinemia possess the variant apo E3. Like the propositus, all five are heterozygous for this variant, suggesting that the disorder in this family is transmitted in a dominant fashion. The variant apo E3 was defective in its ability to bind to lipoprotein receptors, and this functional defect probably contributes to the expression of type III hyperlipoproteinemia in this family.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539388      PMCID: PMC303794          DOI: 10.1172/JCI113988

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Gel electrophoresis of restriction fragments.

Authors:  E Southern
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 3.  Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III).

Authors:  G Utermann
Journal:  Ric Clin Lab       Date:  1982 Jan-Mar

4.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

5.  Cell surface receptor binding of phospholipid . protein complexes containing different ratios of receptor-active and -inactive E apoprotein.

Authors:  R E Pitas; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

6.  Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia.

Authors:  M Fainaru; R W Mahley; R L Hamilton; T L Innerarity
Journal:  J Lipid Res       Date:  1982-07       Impact factor: 5.922

7.  Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.

Authors:  S C Rall; K H Weisgraber; T L Innerarity; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins.

Authors:  R J Havel; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide probes.

Authors:  K H Weisgraber; Y M Newhouse; R W Mahley
Journal:  Biochem Biophys Res Commun       Date:  1988-12-30       Impact factor: 3.575

View more
  20 in total

Review 1.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Mining genetic epidemiology data with Bayesian networks application to APOE gene variation and plasma lipid levels.

Authors:  Andrei Rodin; Thomas H Mosley; Andrew G Clark; Charles F Sing; Eric Boerwinkle
Journal:  J Comput Biol       Date:  2005       Impact factor: 1.479

3.  New restriction endonuclease CviRI cleaves DNA at TG/CA sequences.

Authors:  A Jin; Y Zhang; Y Xia; E Traylor; M Nelson; J L Van Etten
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

4.  NMR studies of the low-density lipoprotein receptor-binding peptide of apolipoprotein E bound to dodecylphosphocholine micelles.

Authors:  D Clayton; I M Brereton; P A Kroon; R Smith
Journal:  Protein Sci       Date:  1999-09       Impact factor: 6.725

5.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

6.  Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene.

Authors:  D A Nickerson; S L Taylor; S M Fullerton; K M Weiss; A G Clark; J H Stengård; V Salomaa; E Boerwinkle; C F Sing
Journal:  Genome Res       Date:  2000-10       Impact factor: 9.043

7.  High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).

Authors:  D A Chappell
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

9.  Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

Authors:  P de Knijff; A M van den Maagdenberg; A F Stalenhoef; J A Leuven; P N Demacker; L P Kuyt; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

10.  Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E.

Authors:  S Fazio; Y L Lee; Z S Ji; S C Rall
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.